Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31397020 | 0.88 | UCHL1 (0.41) | UCHL1FFAR1ALDH1A1PKMCYP1A2 | |
| SCHEMBL24896698 | 0.84 | RAB9A (0.36) | UCHL1FFAR1ALDH1A1GAALMNA | |
| SCHEMBL24896665 | 0.82 | UCHL1 (0.34) | UCHL1SHMT2DGAT1ALDH1A1KDM4E | |
| SCHEMBL31440085 | 0.78 | HSD17B10 (0.37) | UCHL1DGAT1ALDH1A1KDM4EHSD17B1 | |
| SCHEMBL18125388 | 0.77 | SMN1; SMN2 (0.38) | UCHL1FFAR1ALDH1A1KDM4EMAPT | |
| SCHEMBL24896712 | 0.77 | CYP1A2 (0.34) | UCHL1FFAR1CYP1A2 | |
| SCHEMBL26921352 | 0.77 | UCHL1 (0.35) | UCHL1DGAT1ALDH1A1KDM4EHSD17B1 | |
| SCHEMBL21266883 | 0.76 | FFAR1 (0.38) | UCHL1FFAR1KMT2A | |
| SCHEMBL4099087 | 0.76 | FFAR1 (0.57) | UCHL1FFAR1DGAT1MAPTSMN1; SMN2 | |
| SCHEMBL17151558 | 0.75 | ALDH1A1 (0.40) | SHMT2ALDH1A1KDM4EKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421211-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240368117-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2023285497-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022231242-A1 | INDAZOLE COMPOUND HAVING LRRK2 INHIBITORY ACTIVITY | 주식회사 스탠다임 | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | UCHL1 4557/4885SHMT2 4676/4885FFAR1 3384/4885 |
| US-12421211-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | UCHL1 4557/4885SHMT2 4676/4885FFAR1 3384/4885 |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | F12, PM20D2, XDH | UCHL1 4591/4885SHMT2 4815/4885FFAR1 2786/4885 |
| US-20240368117-A1 | HETEROCYCLIC COMPOUNDS | F12, C1R, MRPL21 | UCHL1 4557/4885SHMT2 4676/4885FFAR1 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.